This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counti...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassurin...
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of ...
The pharmaceutical company plans to cut $2 billion in annual expenses by the end...
The biotech is evaluating several cystic fibrosis medicines that could either wo...
The two biotechs, which have lost most of their share value following lucrative ...
Precision medicines biotech Frontier Medicines is leaving behind an unknown numb...
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3...
Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clin...
Cancer biotech Viracta Therapeutics has closed its doors, laying off all employe...
After winning a breakthrough therapy designation for its Hunter syndrome enzyme ...
Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning w...
After their advanced kidney tumors were surgically removed, nine patients were p...
Pfizer is laying down new pieces for its leadership team structure, selecting Je...
Novo Nordisk has bolstered the case for its near-approval hemophilia A drug cand...
Human medicines European public assessment report (EPAR): Omvoh, mirikizumab, Da...
Human medicines European public assessment report (EPAR): Zolgensma, onasemnogen...
Human medicines European public assessment report (EPAR): Hepcludex, bulevirtide...